Phase 3 Clinical Trials With Primary Completion Dates in March 2022

This is a list of Phase 3 trials with primary completion dates in March 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ABEO Abeona Therapeutics Inc. 2022-03-01 Phase 3 NCT04227106 Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
CDTX Cidara Therapeutics, Inc. 2022-03-01 Phase 3 NCT04368559 Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
EBS Emergent BioSolutions Inc. 2022-03-01 Phase 3 NCT05072080 A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317
HLUYY H. Lundbeck A/S 2022-03-01 Phase 3 NCT03548584 A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type
PYPD PolyPid Ltd. 2022-03-01 Phase 3 NCT04411199 D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)
SELB Selecta Biosciences, Inc. 2022-03-01 Phase 3 NCT04513366 A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy
SYNH Syneos Health, Inc. 2022-03-01 Phase 3 NCT02851797 Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
ZEAL Zealand Pharma A/S 2022-03-01 Phase 3 NCT03941236 Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism